RxDoctor Payments Data

Sloane Yu, MD

Pain Medicine · Vancouver, WANPI 1093154551

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,500 of the $42,467 with a category attached, or 64.8%. Stimwave Technologies Incorporated accounts for 79.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $31,495 and has fallen 99.5% since, to $168 in 2025. Among pain medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,467in general payments, 2019–2025

Across 305 payments — averaging $139.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stimwave Technologies Incorporated$34K
  • Boston Scientific$2K
  • Vertiflex, Inc.$2K
  • Si-bone, Inc.$2K
  • Abbott$532
  • SPR Therapeutics, Inc$431
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$27,50065%
  • Travel & lodging$5,85014%
  • Food & beverage$9,11721%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,467 in reported general payments places this provider in the 95th percentile of 124 pain medicine providers in Washington.

See all pain medicine providers in Washington

Medicare billing

Part B allowed, 2024
$122,505
Medicare patients
173
Services billed
3,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine155$32,279
BelbucaBuprenorphine Hcl18$11,958
Gabapentin395$8,663
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen382$6,198
Fentanyl43$6,092
Oxycodone Hcl354$5,168
Pregabalin333$4,316
Duloxetine Hcl154$3,747
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$3,708
Buprenorphine Hcl53$2,706
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen90$2,174
Lidocaine24$1,624
Naloxone Hcl14$1,010
Morphine Sulfate ErMorphine Sulfate22$943
Methocarbamol71$749

Paid to pharmacies, not to this prescriber.

Other pain medicine in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →